Features

What can the markets for bio/pharmaceutical outsourcing expect in 2023? DCAT Value Chain Insights examines key trends and highlights in major manufacturing segments: API and drug-product manufacturing. 

At the J.P. Morgan Annual Healthcare Conference in San Francisco this week, bio/pharma industry executives highlighted their companies’ strategies and key growth initiatives.

What are the top 10 items on the bio/pharma industry’s watchlist for 2023? To continued inflationary pressures, a looming global recession, to moderating global bio/pharma industry growth, DCAT Value Chain Insights examines what is on the industry’s radar. 

There were 37 new molecular entities and therapeutic biologics approved in 2022 by the FDA, significantly down from the 50 new drugs approved in 2021. What were the winners in small molecules and biologics and large and small companies? 

Small-molecule drugs have dominated recent new drug approvals, accounting for almost three-fourths of new drug approvals by the FDA. As we near the end of 2022, have small molecules continued to hold their own? Which drugs made the mark?

Amgen’s pending $28-billion acquisition of the rare-disease bio/pharmaceutical company, Horizon Therapeutics, announced this week, was one of the largest deals in 2022. What other deals stood out this year?

As 2022 comes to a close, what were the largest mergers and acquisitions and expansions made by CDMOs/CMOs in 2022? DCAT Value Chain Insights looks at which companies topped the headlines this year and the leading moves they made.

The International Council for Harmonization (ICH) has adopted its guideline on continuous manufacturing for both drug substances and drug products. What does this mean for the industry and what are…

Escalating energy and raw materials costs was the number one story in the bio/pharmaceutical industry in 2022, but what other news was noteworthy in deal-making, expansions, and industry performance. DCAT Value Chain Insights provides its Top 10 News Stories of 2022.

Akin to the 505 (B)(2) pathway in the US, Medicines for Europe is calling on EU authorities to recognize value-added medicines as separate group of medicines in EU legislation with new approval procedures, innovation frameworks and reimbursement processes.